Poly-ε-caprolactone scaffold and reduced in vitro cell culture: Beneficial effect on compaction and improved valvular tissue formation

Journal of Tissue Engineering and Regenerative Medicine

Volumn 9, Issue 12, 2015, Pages E289-E301

  Brugmans, Marieke M C P ^a,b   Driessen Mol, Anita ^b   Rubbens, Mirjam P ^a   Cox, Martijn A J ^a   Baaijens, Frank P T ^b  

^a Xeltis   (Netherlands)

^b EINDHOVEN UNIVERSITY OF TECHNOLOGY   (Netherlands)

Author keywords

Cell passage; Compaction; Extracellular matrix; Heart valve; Mechanical properties; Scaffold; Tissue engineering

Indexed keywords

BIOMECHANICS; CELL CULTURE; CELL ENGINEERING; COMPACTION; HISTOLOGY; PATIENT TREATMENT; SCAFFOLDS (BIOLOGY); TISSUE; VALVES (MECHANICAL);

4-HYDROXYBUTYRATE; CELL PASSAGE; CELL PHENOTYPE; EXTRACELLULAR MATRICES; HEART VALVES; POLY(GLYCOLIC ACID); POLY(Ε CAPROLACTONE); TISSUE FORMATION; TISSUE-ENGINEERED HEART; TISSUES ENGINEERINGS;

CELLS;

HYDROXYBUTYRIC ACID; POLY 4 HYDROXYBUTYRATE; POLYCAPROLACTONE; POLYGLYCOLIC ACID; UNCLASSIFIED DRUG; POLYESTER;

ADULT; ANIMAL CELL; ARTICLE; CELL CULTURE; CELL EXPANSION; COMPACTION; CONTROLLED STUDY; HEART VALVE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MATERIAL COATING; MATERIALS TESTING; MECHANICAL INTEGRITY; MECHANICS; MIDDLE AGED; NONHUMAN; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PROCESS OPTIMIZATION; RIGIDITY; SHEEP; TISSUE CHARACTERIZATION; TISSUE ENGINEERED HEART VALVE; TISSUE ENGINEERING; TISSUE REGENERATION; TISSUE SCAFFOLD; VALVULAR TISSUE FORMATION; CHEMISTRY; CYTOLOGY; MESENCHYMAL STROMA CELL; METABOLISM; PROCEDURES;

CELLS, CULTURED; HEART VALVES; HUMANS; HYDROXYBUTYRATES; MESENCHYMAL STROMAL CELLS; POLYESTERS; TISSUE ENGINEERING; TISSUE SCAFFOLDS;

EID: 84955196732     PISSN: 19326254     EISSN: 19327005     Source Type: Journal    
DOI: 10.1002/term.1753     Document Type: Article

References (42)

1. Balguid A, Rubbens MP, Mol A, et al. 2007; The role of collagen cross-links in biomechanical behavior of human aortic heart valve leaflets-relevance for tissue engineering, Tissue Eng 13: 1501-1511.
2. Beamish JA, He P, Kottke-Marchant K, et al. 2010; Molecular regulation of contractile smooth muscle cell phenotype: implications for vascular tissue engineering, Tissue Eng Part B Rev 16: 467-491.
3. Butcher JT, Mahler GJ, Hockaday LA. 2011; Aortic valve disease and treatment: the need for naturally engineered solutions, Adv Drug Deliv Rev 63: 242-268.
4. Cesarone CF, Bolognesi C, Santi L. 1979; Improved microfluorometric DNA determination in biological material using 33258 Hoechst, Anal Biochem 100: 188-197.
5. Chen J, Li H, SundarRaj N, et al. 2007, Alpha-smooth muscle actin expression enhances cell traction force. Cell Motil Cytoskeleton 64: 248-257.
6. Christen T, Bochaton-Piallat ML, Neuville P, et al. 1999, Cultured porcine coronary artery smooth muscle cells. A new model with advanced differentiation. Circ Res 85: 99-107.
7. Cummings I, George S, Kelm J, et al. 2011; Tissue-engineered vascular graft remodeling in a growing lamb model: expression of matrix metalloproteinases. Eur J Cardiothorac Surg 41: 167-172.
8. Dijkman PE, Driessen-Mol A, de Heer LM, et al. 2012a; Trans-apical versus surgical implantation of autologous ovine tissue-engineered heart valves. J Heart Valve Dis 21: 670-678.
9. Dijkman PE, Driessen-Mol A, Frese L, et al. 2012b; Decellularized homologous tissue-engineered heart valves as off-the-shelf alternatives to xeno- and homografts. Biomater 33: 4545-4554.
10. Dolezel J, Bartos J, Voglmayr H, et al. 2003, Nuclear DNA content and genome size of trout and human. Cytometry A 51: 127-128
11. Farndale RW, Buttle DJ, and Barrett AJ. 1986; Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue. Biochim Biophys Acta 883: 173-177
12. Gottlieb D, Kunal T, Emani S, et al. 2010; In vivo monitoring of function of autologous engineered pulmonary valve. J Thorac Cardiovasc Surg 139: 723-731.
13. Han J, Liu JY, Swartz DD, et al. 2010; Molecular and functional effects of organismal ageing on smooth muscle cells derived from bone marrow mesenchymal stem cells. Cardiovasc Res 87: 147-155.
14. Hinz B. 2010; The myofibroblast: paradigm for a mechanically active cell. J Biomech 43: 146-155.
15. Hinz B, Phan SH, Thannickal VJ, et al. 2007; The myofibroblast: one function, multiple origins. Am J Pathol 170: 1807-1816.
16. Hoerstrup SP, Cummings MI, Lachat M, et al. 2006; Functional growth in tissue-engineered living, vascular grafts: follow-up at 100weeks in a large animal model. Circulation 114: I159-I166.
17. Hoerstrup SP, Sodian R, Daebritz S, et al. 2000; Functional living trileaflet heart valves grown in vitro. Circulation 102: III44-III49.
18. Hoffman-Kim D, Maish MS, Krueger PM, et al. 2005; Comparison of three myofibroblast cell sources for the tissue engineering of cardiac valves. Tissue Eng 11: 288-301.
19. Huszar G, Maiocco J, Naftolin F. 1980; Monitoring of collagen and collagen fragments in chromatography of protein mixtures. Anal Biochem 105: 424-429.
20. Junqueira LC, Bignolas G, Brentani RR. 1979; Picrosirius staining plus polarization microscopy, a specific method for collagen detection in tissue sections. Histochem J 11: 447-455.
21. Klinger RY, Blum JL, Hearn B, et al. 2006; Relevance and safety of telomerase for human tissue engineering. Proc Nati Acad Sci U S A 103: 2500-2505.
22. Klouda L, Vaz C, Mol A, et al. 2008; Effect of biomimetic conditions on mechanical and structural integrity of PGA/P4HB and electrospun PCL scaffolds. J Mater Sci Mater Med 19: 1137-1144.
23. Kortsmit J, Driessen NJ, Rutten MC, et al. 2009; Real time, non-invasive assessment of leaflet deformation in heart valve tissue engineering. Ann Biomed Eng 37: 532-541.
24. Lacolley P, Regnault V, Nicoletti A, et al. 2012; The vascular smooth muscle cell in arterial pathology: a cell that can take on multiple roles. Cardiovasc Res 95: 194-204.
25. Mendelson K, Schoen F. 2006; Heart Valve Tissue Engineering: Concepts, Approaches, Progress, and Challenges. Ann Biomed Eng 34: 1799-1819.
26. Mol A, Driessen NJ, Rutten MC, et al. 2005a; Tissue engineering of human heart valve leaflets: a novel bioreactor for a strain-based conditioning approach. Ann Biomed Eng 33: 1778-1788.
27. Mol A, Rutten MC, Driessen NJ, et al. 2006; Autologous human tissue-engineered heart valves: prospects for systemic application. Circulation 114: I152-I158.
28. Mol A, Smits AI, Bouten CV, et al. 2009; Tissue engineering of heart valves: advances and current challenges. Expert Rev Med Devices 6: 259-275.
29. Mol A, van Lieshout MI, Dam-de Veen CG, et al. 2005b; Fibrin as a cell carrier in cardiovascular tissue engineering applications. Biomaterials 26: 3113-3121.
30. Rabkin-Aikawa E, Farber M, Aikawa M, et al. 2004; Dynamic and reversible changes of interstitial cell phenotype during remodeling of cardiac valves. J Heart Valve Dis 13: 841-847.
31. Ragnauth CD, Warren DT, Liu Y, et al. 2010; Prelamin A acts to accelerate smooth muscle cell senescence and is a novel biomarker of human vascular aging. Circulation 121: 2200-2210.
32. Rensen SS, Doevendans PA, van Eys GJ. 2007; Regulation and characteristics of vascular smooth muscle cell phenotypic diversity. Neth Heart J 15: 100-108.
33. Safwani WK, Makpol S, Sathapan S, et al. 2012; The impact of long-term in vitro expansion on the senescence-associated markers of human adipose-derived stem cells. Appl Biochem Biotechnol 166: 2101-2113.
34. Schmidt D, Dijkman PE, Driessen-Mol A, et al. 2010; Minimally-invasive implantation of living tissue engineered heart valves: a comprehensive approach from autologous vascular cells to stem cells. J Am Coll Cardiol 56: 510-520.
35. Shahbudin H. 2003; Choice of prosthetic heart valve for adult patients. J Am Coll Cardiol 41: 893-904.
36. Teng B, Ansari HR, Oldenburg PJ, et al. 2006; Isolation and characterization of coronary endothelial and smooth muscle cells from A1 adenosine receptor-knockout mice. Am J Physiol Heart Circ Physiol, 290: H1713-H1720.
37. van der Loop FT, Schaart G, Timmer ED, et al. 1996; Smoothelin, a novel cytoskeletal protein specific for smooth muscle cells. J Cell Biol 134: 401-411.
38. van Geemen D, Driessen-Mol A, Grootzwagers LG, et al. 2012; Variation in tissue outcome of ovine and human engineered heart valve constructs: relevance for tissue engineering. Regen Med 7: 59-70.
39. van Vlimmeren MA, Driessen-Mol A, Oomens CW, et al. 2011; An in vitro model system to quantify stress generation, compaction, and retraction in engineered heart valve tissue. Tissue Eng Part C Methods 17: 983-991.
40. van Vlimmeren MA, Driessen-Mol A, Oomens CW, et al. 2012; Passive and active contributions to generated force and retraction in heart valve tissue engineering. Biomech Model Mechanobiol 11: 1015-1027.
41. Weber B, Scherman J, Emmert MY, et al. 2011; Injectable living marrow stromal cell-based autologous tissue engineered heart valves: first experiences with a one-step intervention in primates. Eur Heart J 32: 2830-2840.
42. Yacoub MH, Takkenberg JJ. 2005; Will heart valve tissue engineering change the world? Nat Clin Pract Cardiovasc Med 2: 60-61.